Merck & Co. are developing a new drug that is said to help improve sleep and people suffering from insomnia. The drug is called the MK-4305 and belongs to a new class of sleep drugs which inhibit production of orexins in the brain, blocking stimulation of the brain’s arousal system.
Orexin is a neuropeptide that is believed to play a key role in regulation of the brain’s sleep/wake process.
The MK-4305 is made up of different dosages which are now being used in studies. 40 mg and 20 mg doses are being used on younger patients while elderly folks are using the 30 mg and 15 mg dosages.
There were no reports of serious adverse side effects. The most common side effects included upper respiratory tract infection, urinary tract infection, dizziness, drowsiness on waking, headache and vivid dreams.
